EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Association Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR ‐Mutated Advanced NSCLC : The Impact of Post‐Progression Management

Issei Oi iD, Kohei Fujita iD, Takuma Imakita, Mitsuhiro Tukino, Tetsuo Noguchi, Yuta Okada, Saiki Yoshimura, Naoki Fujimoto, Shogo Toyama, Atsuko Watanabe, Takanori Ito, Ryosuke Kaku und 5 weitere

Thoracic Cancer · 2026

DOI: 10.1111/1759-7714.70328 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Thoracic Cancer, 2026. Verfasst von Issei Oi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Kyoto, Japan. Hauptthemen laut MEDLINE: Aniline Compounds, Acrylamides, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung. Die Arbeit nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Osimertinib is the standard first‐line treatment for epidermal growth factor receptor (EGFR)‐mutated advanced non‐small cell lung cancer (NSCLC). However, the impact of dose‐reduction on survival and the role of post‐progression management in real‐world settings remain unclear.

Methods

We conducted a multi‐institutional retrospective cohort study on patients with EGFR‐mutated advanced NSCLC who received first‐line osimertinib between January 2018 and December 2023. Patients were classified into dose‐reduced and full‐dose groups. Primary endpoints were time to treatment failure (TTF) and overall survival (OS). The subsequent treatment after progression was also exploratively assessed to evaluate the impact of initial dose modification on the entire treatment sequence.

Results

A total of 90 patients were analyzed, consisting of 61 patients in the full‐dose group and 29 in the dose‐reduction group. Median follow‐up was 21.5 months (IQR 9.1–37.2). The dose‐reduced group had significantly worse baseline performance status (PS) (PS 2–3: 37.9% vs. 14.8%, p = 0.014). Despite this, dose reduction showed no significant impact on TTF (adjusted HR 0.66, 95% CI 0.40–1.10, p = 0.11) or OS (HR 0.97, 95% CI 0.59–1.58, p = 0.89). Multivariate analysis revealed that transition to best supportive care (BSC) after progression, rather than initial dose reduction, was associated with OS (hazard ratio, 7.40; p < 0.0001). The proportions of patients receiving subsequent chemotherapy were comparable between the groups.

Conclusions

Osimertinib dose reduction in the first‐line setting was not associated with inferior OS, suggesting that appropriate dose modification helps maintain PS. Transition to BSC after progression, rather than initial dose intensity, was associated with poor prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Aniline CompoundsAcrylamidesLung NeoplasmsCarcinoma, Non-Small-Cell LungHumansIndolesPyrimidinesFemaleRetrospective StudiesErbB ReceptorsMaleMutationAgedMiddle AgedTreatment OutcomeDisease Progression

Stichwörter der Autor:innen

EGFR mutationbest supportive caredose reductionnon‐small cell lung cancerosimertiniboverall survivaltime to treatment failure

Substanzen

IndolesosimertinibPyrimidinesAniline CompoundsAcrylamidesErbB ReceptorsEGFR protein, human

Autor:innen und Institutionen

  • Division of Respiratory Medicine, Center for Respiratory Diseases, National Hospital Organization Kyoto Medical Center, Kyoto, Kyoto, Japan.
  • Department of Respiratory Medicine, Hikone Municipal Hospital, Hikone, Shiga, Japan.
  • Department of Respiratory Medicine and Thoracic Surgery, Nagahama City Hospital, Nagahama, Shiga, Japan.
  • Department of Thoracic Surgery, Center for Respiratory Medicine, National Hospital Organization Kyoto Medical Center, Kyoto, Kyoto, Japan.

ORCID-Profile: Issei Oi, Kohei Fujita, Kiminobu Tanizawa

Zitieren

APA

Oi, I., Fujita, K., Imakita, T., Tukino, M., Noguchi, T., Okada, Y., Yoshimura, S., Fujimoto, N., Toyama, S., Watanabe, A., Ito, T., Kaku, R., Kanai, O., Ohuchi, M., Tanizawa, K., Sawai, S., & Mio, T. (2026). Association Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR ‐Mutated Advanced NSCLC : The Impact of Post‐Progression Management. Thoracic Cancer. https://doi.org/10.1111/1759-7714.70328

Vancouver

Oi I, Fujita K, Imakita T, Tukino M, Noguchi T, Okada Y, et al. Association Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR ‐Mutated Advanced NSCLC : The Impact of Post‐Progression Management. Thoracic Cancer. 2026. doi:10.1111/1759-7714.70328

BibTeX
@article{Oi2026,
  author = {Oi, Issei and Fujita, Kohei and Imakita, Takuma and Tukino, Mitsuhiro and Noguchi, Tetsuo and Okada, Yuta and Yoshimura, Saiki and Fujimoto, Naoki and Toyama, Shogo and Watanabe, Atsuko and Ito, Takanori and Kaku, Ryosuke and Kanai, Osamu and Ohuchi, Masatsugu and Tanizawa, Kiminobu and Sawai, Satoru and Mio, Tadashi},
  title = {Association Between Osimertinib Dose Reduction and Treatment Outcomes in First‐Line EGFR ‐Mutated Advanced NSCLC : The Impact of Post‐Progression Management},
  journal = {Thoracic Cancer},
  year = {2026},
  doi = {10.1111/1759-7714.70328}
}
Kostenlos starten →